Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study
Senthilkumar Sankararaman, Ruitao Liu, Xinyu Sun, Mauricio Retuerto, Terri Schindler, Erica Roesch, Thomas J. Sferra, Mitch Drumm, Mahmoud Ghannoum, Liangliang Zhang
TL;DR
This study compares the gut microbiome of children with cystic fibrosis who received a specific drug combination versus those who did not, finding no major differences but noting some trends.
Contribution
The study is a pilot investigation into the impact of ETI therapy on the gut microbiome in children with cystic fibrosis.
Findings
No significant differences in alpha diversity of the bacteriome and mycobiome were found between groups.
Alpha diversity showed a negative trend with the duration of ETI therapy.
Firmicutes, Proteobacteria, Ascomycota, and Basidiomycota were the most abundant and consistent microbial groups across all samples.
Abstract
Prior studies in people with cystic fibrosis (CF) demonstrated a positive impact of ivacaftor on the stool microbiome. However, studies evaluating the impact of elexacaftor–tezacaftor–ivacaftor (ETI) on gut dysbiosis are limited. In this prospective, observational study, we evaluated the differences in stool microbiome in children (aged 2–17 years) with CF who were treated with ETI for at least two months and compared with children with CF who did not receive ETI. We also included healthy siblings as controls. There were no significant differences in the demographics between the groups. There were no significant differences in alpha diversity between the groups for both bacteriome and mycobiome. Alpha diversity showed a negative trend with the duration of ETI therapy for both bacteriome and mycobiome. Firmicutes and Proteobacteria were the most abundant phyla and core members across all…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCystic Fibrosis Research Advances · Gut microbiota and health · Bacterial biofilms and quorum sensing